17 April 2015 - - Results from a multicenter study evaluating the effects of investigational compound brexpiprazole as monotherapy in adult patients with schizophrenia have been published online by the American Journal of Psychiatry, Japanese drugmaker Otsuka said on Friday.  The study, "Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial" evaluated the efficacy and tolerability of brexpiprazole in adult patients with an acute exacerbation of schizophrenia. Brexpiprazole is a novel investigational psychotropic compound discovered by Otsuka and under co-development with Danish brain disorder specialist Lundbeck. The Phase III trial randomized 636 patients with acute schizophrenia to fixed doses of brexpiprazole (0.25mg, 2mg or 4mg) or placebo (randomized 1:2:2:2), respectively, for six weeks. Results indicated that brexpiprazole 2mg and 4mg demonstrated significant improvement versus placebo in the primary endpoint of change from baseline to Week six in PANSS (Positive and Negative Syndrome Scale). Total Score: (0.25mg: -14.90; 2mg: -20.73, p=